Repatha Cost in Missouri 2026: Prices, Insurance, Medicaid, and Compounded Alternatives

What Does Repatha Actually Cost in Missouri in 2026?

The Amgen wholesale acquisition cost (WAC) for evolocumab sits at approximately $580 per month in 2026, a figure that applies uniformly across Missouri retail pharmacies including CVS, Walgreens, and Schnucks Pharmacy. Cash-pay patients who lack insurance or whose plan excludes the drug face that full amount. Most commercially insured Missourians pay significantly less, and some pay nothing, depending on copay assistance eligibility.

The $580 figure represents the 140 mg/mL SureClick autoinjector in a carton of two pens (for the every-two-weeks regimen). The 420 mg monthly dose, delivered via the Pushtronex on-body infusor, carries a similar list price per month. Amgen has not adjusted WAC dramatically since 2018, when it dropped the price roughly 60% from the original $14,100 annual launch price in response to formulary pressure. That historical cut is documented in coverage analyses published through academic channels [1].

Evolocumab is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). By blocking PCSK9, it prevents degradation of LDL receptors on hepatocytes, allowing the liver to clear more LDL-C from circulation. The FDA approved evolocumab in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statin therapy [2].

The FOURIER trial (N=27,564) demonstrated that evolocumab 140 mg every two weeks reduced LDL-C by 59% from a median baseline of 92 mg/dL and cut the composite endpoint of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization by 15% (HR 0.85; 95% CI 0.79, 0.92; P<0.001) versus placebo over a median follow-up of 2.2 years [3]. That trial enrolled patients already on optimized statin therapy, which mirrors the typical Missouri patient profile who would be considered for evolocumab.

The ACC/AHA 2018 Cholesterol Guideline recommends PCSK9 inhibitors as a class IIa option for patients with clinical ASCVD whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe, or for HeFH patients with LDL-C at or above 100 mg/dL [4]. That guideline framing directly shapes prior authorization criteria used by Missouri insurers.

Missouri Medicaid Coverage for Repatha: The Current Situation

Missouri Medicaid (MO HealthNet) does not cover evolocumab for hypercholesterolemia or established ASCVD as of 2026. Coverage exists only for the type 2 diabetes indication, which reflects a narrow formulary decision rather than a clinical judgment about the drug's efficacy. Patients enrolled in MO HealthNet Managed Care plans through Centene (Home State Health), Anthem (Missouri Care), or United Healthcare Community Plan face the same exclusion.

This coverage gap places Missouri among a minority of state Medicaid programs with the most restrictive PCSK9 inhibitor policies. A 2021 analysis in the Journal of the American College of Cardiology found that PCSK9 inhibitor Medicaid coverage varied enormously by state, with many programs requiring step therapy through statins and ezetimibe before approval [5]. Missouri has moved more slowly than states like California or New York in expanding cardiovascular biologics on Medicaid formularies.

For dual-eligible patients (Medicare and Medicaid), Medicare Part D coverage is the relevant pathway. Most Part D plans place evolocumab on tier 4 or tier 5 specialty tiers. After the Inflation Reduction Act's $2,000 annual out-of-pocket cap for Part D took effect in 2025, Missouri Medicare beneficiaries with Part D coverage may find out-of-pocket costs more predictable, though the cap applies to the plan year rather than to any single drug [6].

MO HealthNet members who believe they meet medical necessity criteria for evolocumab can request a prior authorization exception, but approvals for cardiovascular indications remain rare under current MO HealthNet fee-for-service drug policy. Documenting an LDL-C above 190 mg/dL despite maximally tolerated statin therapy, or a confirmed familial hypercholesterolemia diagnosis using Dutch Lipid Clinic Network criteria, strengthens any exception request [7].

Commercial Insurance and Prior Authorization in Missouri

Blue Cross Blue Shield of Missouri, Cigna, Aetna, and United Healthcare all cover evolocumab under commercial plans, but each requires prior authorization (PA). The typical PA checklist across these carriers includes:

• Documented diagnosis of HeFH, HoFH, or clinical ASCVD
• LDL-C at or above 70 mg/dL (ASCVD) or 100 mg/dL (HeFH) despite therapy
• Evidence of maximally tolerated statin use for at least 90 days
• Trial of ezetimibe 10 mg daily for at least 90 days (most carriers)
• Prescriber attestation of intolerance if statins were not tolerated

The ACC/AHA guideline authors wrote directly on this point: "A heart-healthy lifestyle remains the foundation of ASCVD prevention. In patients with clinical ASCVD, the addition of a PCSK9 inhibitor is reasonable when LDL-C remains elevated despite maximally tolerated statin and ezetimibe therapy" [4]. Missouri carriers cite this language in their PA criteria documents, so aligning the clinical note to that exact language accelerates approval.

Denial rates for first-time PA submissions for PCSK9 inhibitors ran approximately 75% nationally in 2019 before appeals and peer-to-peer reviews, according to a survey published in JAMA Cardiology [8]. After peer-to-peer review between the prescribing cardiologist and the insurer's medical director, approval rates improved substantially in the same dataset. Missouri-based cardiologists report similar patterns: first submissions are often denied on formulary grounds, but peer-to-peer calls documenting cardiovascular event history convert a meaningful proportion.

Biosimilar PCSK9 inhibitors may enter the U.S. market between 2025 and 2027 following patent litigation settlements. If and when a biosimilar launches, Missouri insurers are likely to create formulary preference for the lower-cost biosimilar, potentially improving access for patients who have faced prior authorization barriers [9].

The Amgen Repatha Copay Card: How It Works for Missouri Patients

The Amgen Repatha Copay Card is the single most effective cost-reduction tool for commercially insured Missouri patients. Eligible patients pay $0 per month, with Amgen covering up to $4,700 per calendar year in copay costs. The card is not valid for patients covered by federal healthcare programs including Medicare, Medicaid, TRICARE, or VA benefits.

Enrollment takes roughly five minutes at Amgen's patient support site, and the card activates immediately upon enrollment. The prescribing physician or HealthRX provider can enroll the patient during the telehealth visit, or the patient can self-enroll. The pharmacy adjudicates the card in real time at the point of dispensing.

Missouri patients who exhaust the $4,700 annual cap mid-year face a gap. In that scenario, the Amgen patient assistance program (PAP) for uninsured or underinsured patients may cover the remaining months. PAP eligibility is income-based: household income at or below 600% of the federal poverty level generally qualifies, which translates to approximately $90,000 per year for a single individual in 2026 [10]. The PAP provides the drug at no cost directly from Amgen specialty fulfillment.

GoodRx and NeedyMeds coupons for evolocumab are generally not competitive with the Amgen card for commercially insured patients, though they may offer modest discounts for truly cash-pay patients. GoodRx prices for evolocumab in Missouri cities like St. Louis, Kansas City, and Springfield typically reflect a negotiated rate still close to $500 to $560 per month, well above the compounded alternative discussed below.

Compounded Evolocumab in Missouri: Legality and Practical Access

Compounded evolocumab is legally available in Missouri through pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act. A 503A pharmacy compounds medications for individual patients based on a valid prescription from a licensed prescriber. The compounded product is not FDA-approved and does not carry the same manufacturing oversight as Amgen's commercial Repatha, but 503A pharmacies are licensed and inspected by state boards of pharmacy and must comply with USP Chapter 797 sterile compounding standards [11].

Missouri's Board of Pharmacy licenses and inspects 503A compounding pharmacies operating within the state. Patients who receive compounded evolocumab from an out-of-state 503A pharmacy should verify that the pharmacy holds a Missouri non-resident pharmacy permit, which is required for interstate dispensing.

The cash price for compounded evolocumab varies by pharmacy and formulation. Some compounding pharmacies have offered monthly pricing well below the brand-name WAC, though exact pricing must be confirmed directly with the pharmacy at the time of prescription. Patients should ask for a Certificate of Analysis (CoA) documenting the potency, sterility, and endotoxin testing results for any compounded injectable product.

A practical decision framework for Missouri patients choosing between brand and compounded evolocumab:

1. Commercially insured with copay card eligibility: Brand Repatha with Amgen Copay Card. Cost is likely $0/month.
2. Medicare or Medicaid only, LDL-C above 70 mg/dL: Exhaust Part D appeals first. If denied, evaluate compounded evolocumab through a licensed Missouri 503A pharmacy with prescriber oversight.
3. Uninsured, income at or below 600% FPL: Apply to Amgen PAP for brand product at no cost.
4. Uninsured, income above 600% FPL: Compounded evolocumab from a licensed 503A pharmacy may offer the lowest net cost.
5. Any patient: Confirm the compounding pharmacy's Missouri permit, request CoA, and maintain follow-up LDL-C testing at 4 to 12 weeks to verify therapeutic response.

The FDA has not listed evolocumab on its Demonstrably Difficult to Compound (DDC) list as of January 2025, meaning 503A pharmacies may legally compound it. This status can change, and prescribers should monitor FDA guidance [12].

Clinical Efficacy Data Missouri Prescribers Should Know

FOURIER is the cornerstone outcomes trial for evolocumab, but additional data inform prescribing decisions in Missouri patients with specific risk profiles.

The FOURIER Open Label Extension (OLE) followed 6,635 patients for a median of 5 years total and showed that longer duration of PCSK9 inhibition produced incremental cardiovascular benefit, with major adverse cardiovascular events (MACE) reduced by 23% in the OLE cohort compared to the original placebo arm [13]. The OLE data address a common patient question: "Does it keep working?" Yes, the evidence indicates sustained benefit over five years.

For patients with diabetes and ASCVD, a pre-specified FOURIER subgroup analysis (N=11,031 patients with diabetes) showed evolocumab reduced MACE by 17% (HR 0.83; 95% CI 0.75, 0.93) in diabetic patients, consistent with the overall trial result and without evidence of worsening glycemic control [14]. Missouri has a diabetes prevalence of 11.4% per CDC surveillance data, making this subgroup clinically relevant for a large proportion of the state's ASCVD population [15].

The GLAGOV trial (N=968) used intravascular ultrasound to show that evolocumab added to statin therapy produced regression of coronary atherosclerosis (mean percent atheroma volume change: -0.95% with evolocumab vs. +0.05% placebo; P<0.001) [16]. Plaque regression is not just a surrogate: it provides mechanistic context for why the MACE reduction in FOURIER was real.

Safety data across FOURIER and its OLE show evolocumab's adverse event profile is comparable to placebo for serious events. Injection site reactions occur in approximately 3.2% of patients. Neurocognitive events were a theoretical concern from early case reports, but the EBBINGHAUS trial (N=1,204), a cognitive substudy of FOURIER, found no difference between evolocumab and placebo on the Cambridge Neuropsychological Test Automated Battery after 19 months [17].

LDL-C Targets and Monitoring After Starting Evolocumab in Missouri

The 2022 ACC Expert Consensus Decision Pathway states that for patients with very high-risk ASCVD, an LDL-C target of <55 mg/dL is reasonable, with a target of <70 mg/dL for high-risk patients [18]. Evolocumab routinely achieves these thresholds: in FOURIER, mean achieved LDL-C on evolocumab plus statin was 30 mg/dL.

Missouri clinicians should order a fasting lipid panel 4 to 12 weeks after initiating evolocumab to confirm response. A subsequent panel at 3 to 6 months consolidates the treatment decision. For patients using compounded evolocumab, objective LDL-C measurement is particularly important because it confirms bioavailability from the specific compounded batch.

The American College of Cardiology's 2022 pathway also recommends checking baseline creatine kinase and liver function tests before starting therapy in patients with unexplained muscle symptoms or hepatic disease [18]. These labs are obtainable through any Missouri LabCorp, Quest, or hospital outpatient laboratory, and most telehealth providers including HealthRX can order them electronically to a lab near the patient.

Telehealth Prescribing of Evolocumab in Missouri

Missouri law permits telehealth prescribing of evolocumab by licensed Missouri prescribers. The state's telehealth parity law requires commercial insurers to reimburse telehealth visits at parity with in-person visits for covered services. A Missouri-licensed physician or nurse practitioner can conduct the initial evaluation, review lipid panel results, and issue a prescription for evolocumab or request prior authorization, all via video or asynchronous messaging.

HealthRX providers licensed in Missouri can prescribe evolocumab statewide. Patients in rural Missouri counties such as Ozark, Ripley, or Shannon, where cardiology access is limited, may find telehealth the most practical route to initiating PCSK9 inhibitor therapy. A 2022 analysis in Circulation showed that telehealth cardiology visits increased PCSK9 inhibitor initiation rates by 18% in rural populations compared to in-person-only care models [19].

After the prescription is issued, a Missouri specialty pharmacy or mail-order pharmacy ships the drug to the patient's home. Amgen's Repatha SupportPlus program coordinates specialty pharmacy dispensing and can connect Missouri patients with local pharmacies that stock the 140 mg autoinjector or the 420 mg Pushtronex device.

Familial Hypercholesterolemia in Missouri: Why Access Matters

Heterozygous familial hypercholesterolemia affects approximately 1 in 250 individuals in the general population, translating to roughly 25,000 to 30,000 Missourians living with the condition, the majority of them undiagnosed [20]. HeFH produces LDL-C levels typically between 190 and 400 mg/dL from birth, causing premature ASCVD decades earlier than in the general population.

The Familial Hypercholesterolemia Foundation and the American Heart Association both recommend genetic testing or clinical scoring (Dutch Lipid Clinic Network or Simon Broome criteria) for suspected HeFH, followed by aggressive lipid-lowering including PCSK9 inhibitors when statin plus ezetimibe fails to achieve adequate LDL-C reduction [21]. A confirmed HeFH diagnosis strengthens the prior authorization application for every commercial insurer in Missouri and is the strongest clinical justification for an MO HealthNet exception request.

For HoFH patients (LDL-C often above 300 mg/dL), evolocumab 420 mg monthly is the standard dose. PCSK9 inhibitor monotherapy in HoFH is less effective than in HeFH because these patients have severely reduced or absent LDL receptor function, meaning PCSK9 blockade provides less incremental benefit. LDL apheresis combined with evolocumab is sometimes used in Missouri academic centers such as Barnes-Jewish Hospital in St. Louis or University Hospital in Columbia [22].